Chesley Taft & Associates LLC / ABT
Chesley Taft & Associates LLC’s Abbott Laboratories Position
Does Chesley Taft & Associates LLC own Abbott Laboratories (ABT)? Yes — 279.7K shares worth $25M (+0.99% of its 13F portfolio) as of Q2 2026, up from 242.6K shares the prior filed quarter.
Position Value
$25M
Q2 2026
Shares
279.7K
% of Portfolio
+0.99%
Quarters Held
31
currently held
Position History ABT
Reported value by quarter
| Quarter | Shares | Value | % of Portfolio |
|---|---|---|---|
| Q2 2026 | 279.7K | $25M | +0.99% |
| Q1 2026 | 242.6K | $25M | +1.04% |
| Q4 2025 | 241.8K | $30M | +1.20% |
| Q3 2025 | 223.2K | $30M | +1.27% |
| Q2 2025 | 232.7K | $32M | +1.41% |
| Q1 2025 | 234.1K | $31M | +1.50% |
| Q4 2024 | 237.7K | $27M | +1.25% |
| Q3 2024 | 236.2K | $27M | +1.28% |
| Q2 2024 | 238.0K | $25M | +1.24% |
| Q1 2024 | 237.3K | $27M | +1.38% |
| Q4 2023 | 237.5K | $26M | +1.47% |
| Q3 2023 | 236.4K | $23M | +1.49% |
| Q2 2023 | 236.4K | $26M | +1.58% |
| Q1 2023 | 239.4K | $24M | +1.59% |
| Q4 2022 | 241.0K | $26M | +1.82% |
| Q3 2022 | 275.8K | $27M | +1.96% |
| Q2 2022 | 277.7K | $30M | +2.06% |
| Q1 2022 | 279.2K | $33M | +1.93% |
| Q4 2021 | 283.4K | $40M | +2.06% |
| Q3 2021 | 283.1K | $33M | +1.91% |
| Q2 2021 | 283.8K | $33M | +1.89% |
| Q1 2021 | 289.1K | $35M | +2.07% |
| Q4 2020 | 296.7K | $32M | +2.08% |
| Q3 2020 | 306.9K | $33M | +2.37% |
| Q2 2020 | 311.7K | $29M | +2.17% |
| Q1 2020 | 316.5K | $25M | +2.27% |
| Q4 2019 | 323.5K | $28M | +2.02% |
| Q3 2019 | 324.7K | $27M | +2.10% |
| Q2 2019 | 324.8K | $27M | +2.13% |
| Q1 2019 | 325.6K | $26M | +2.17% |
| Q4 2018 | 328.2K | $24M | +2.29% |
Common-stock position only; options are excluded. Quarters where the fund filed no 13F or reported no position are absent. See Chesley Taft & Associates LLC’s full portfolio or all institutional holders of ABT.